A kind of lenvatinib mesylate solid dispersion and its preparation method and application

A solid dispersion, lenvatinib technology, applied in the field of medicine, can solve the problem of low solubility of lenvatinib mesylate

Active Publication Date: 2022-03-08
LEPU PHARMACEUTICAL CO LTD
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Although the crystal forms are different, the solubility of lenvatinib mesylate is not high. According to the patent US20180155291A, the solubility of crystal form C and crystal form M in simulated feeding state intestinal fluid are 0.0003mg / mL and 0.0004mg / L respectively

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of lenvatinib mesylate solid dispersion and its preparation method and application
  • A kind of lenvatinib mesylate solid dispersion and its preparation method and application
  • A kind of lenvatinib mesylate solid dispersion and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Embodiment 1: Preparation of lenvatinib mesylate solid dispersion (I)

[0023] Add 24.5g of lenvatinib mesylate into 150ml of acetone / water mixed solvent (mass ratio, 10:1), heat up to about 55°C, stir to dissolve, add 15g of hydroxypropyl cellulose evenly, stir to dissolve ,spare. Add 245g of calcium carbonate into the fluidized bed, set the inlet air temperature at 60°C, and when the material temperature reaches 25°C, spray the lenvatinib mesylate solution into the fluidized bed. After spraying, add 10mL of acetone / water mixed solvent (mass ratio, 10:1) to spray into the fluidized bed, and dry until the water content is below 1.0%. After grinding, 268.23 g of solid dispersion was obtained, yield 94.28%.

Embodiment 2

[0024] Embodiment 2: Preparation of lenvatinib mesylate solid dispersion (II)

[0025] Add 49g of lenvatinib mesylate into 200ml of acetone / water mixed solvent (mass ratio, 10:1), heat up to about 55°C, stir to dissolve, add 30g of hypromellose evenly, stir to dissolve, spare. Add 490g of calcium carbonate into the high-shear wet granulator, open the cutting knife and the granulating knife, and atomize and spray the lenvatinib mesylate solution. After that, put the material into a blast drying oven at 60°C to dry to a moisture content below 1%. After grinding, the collected material was 529.21g, and the yield was 93.01%.

Embodiment 3

[0026] Embodiment 3: Preparation of lenvatinib mesylate solid dispersion (III)

[0027] Add 25g of lenvatinib mesylate into 150ml of acetone / water mixed solvent (mass ratio, 10:1), heat up to about 55°C, stir to dissolve, add 15g of hydroxypropyl cellulose evenly, stir to dissolve, spare. Add 200g of mannitol into the fluidized bed, set the inlet air temperature to 60°C, and when the material temperature reaches 25°C, spray the lenvatinib mesylate solution into the fluidized bed. After spraying, add 10mL of acetone / water mixed solvent (mass ratio, 10:1) to spray into the fluidized bed, and dry until the water content is below 1.0%. After grinding, 213.34 g of solid dispersion was obtained, yield 88.89%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a lenvatinib mesylate solid dispersion, a preparation method and application thereof, and belongs to the field of chemical pharmacy. The solid dispersion is obtained by the following method, dissolving lenvatinib mesylate in a solvent, then adding a cellulose derivative, stirring to dissolve, spraying onto a carrier, and removing the solvent by drying to obtain methanesulfonate A lenvatinib solid dispersion, the carrier is one or a mixture of two or more in any proportion among inorganic calcium salt, mannitol, sorbitol, microcrystalline cellulose and low-substituted hydroxypropyl cellulose. The lenvatinib mesylate capsule prepared by the method of the invention improves the solubility, dissolution rate and stability of the lenvatinib mesylate, so that it can better exert its therapeutic effect.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to a solid dispersion of lenvatinib mesylate and a preparation method and application thereof. Background technique [0002] Lenvatinib mesylate is a kinase inhibitor, which mainly inhibits angiogenesis by inhibiting vascular endothelial growth factor receptor VEGFR and fibroblast growth factor receptor FGFR, thereby exerting an anti-tumor effect. Developed by Japan's Eisai Pharmaceutical Company, it was approved by the US FDA on February 13, 2015 for the treatment of thyroid cancer. Approved in China on September 4, 2018, the indication is unresectable hepatocellular carcinoma that has not received systemic therapy before. [0003] Yuanyan Eisai Pharmaceutical Co., Ltd. applied for a patent CN101337933B disclosing crystal forms A, B and C of lenvatinib mesylate for use in preparations. Suzhou Jingyun Pharmaceutical Technology Co., Ltd. applied for a patent US2018015...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/14A61K9/48A61K47/38A61K47/02A61K31/47A61P35/00
CPCA61K9/146A61K9/143A61K9/1652A61K31/47A61P35/00
Inventor 杜阳森骆献丽付晓宁李海峰
Owner LEPU PHARMACEUTICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap